Contact
searchSearch
HMP Global

Dermatology Topic Center

Advanced Squamous Cell Carcinoma of the Anal Canal
Videos
Evaluating Retifanlimab for Advanced Squamous Cell Carcinoma of the Anal Canal in the Frontline Setting
03/31/2026
Lingbin Meng, MD, PhD
Lingbin Meng, MD, discusses how adding retifanlimab to chemotherapy may reshape frontline treatment for advanced squamous cell carcinoma of the anal canal.
Lingbin Meng, MD, discusses how adding retifanlimab to chemotherapy may reshape frontline treatment for advanced squamous cell carcinoma of the anal canal.
Lingbin Meng, MD, discusses how...
03/31/2026
First Report Managed Care
News
Immune Marker Profiles Distinguish cSCC From BCC in Tumor Microenvironment Study
12/04/2025
Grace Taylor, MS, MA
A comprehensive tumor microenvironment analysis uncovers key immune marker patterns that sharply distinguish cutaneous squamous cell carcinoma (cSCC) from basal cell carcinoma (BCC), pointing to new opportunities for clinical risk...
A comprehensive tumor microenvironment analysis uncovers key immune marker patterns that sharply distinguish cutaneous squamous cell carcinoma (cSCC) from basal cell carcinoma (BCC), pointing to new opportunities for clinical risk...
A comprehensive tumor...
12/04/2025
First Report Managed Care
News
First-Line Nivolumab Shows Promising Response Rates in Advanced Basal Cell Carcinoma
11/25/2025
Grace Taylor, MS, MA
A study presented at the 2025 European Society for Medical Oncology Congress shows that first-line nivolumab significantly improves response rates in advanced basal cell carcinoma, offering new hope for patients beyond current second-line...
A study presented at the 2025 European Society for Medical Oncology Congress shows that first-line nivolumab significantly improves response rates in advanced basal cell carcinoma, offering new hope for patients beyond current second-line...
A study presented at the 2025...
11/25/2025
First Report Managed Care
News
Study Reveals Distinct Psychosocial Burden Profiles Among Patients With Vitiligo
06/17/2025
Grace Taylor, MS, MA
An international study reveals that patients with vitiligo experience varying levels of emotional and social burden, often independent of visible disease severity, underscoring the need for more holistic clinical assessments.
An international study reveals that patients with vitiligo experience varying levels of emotional and social burden, often independent of visible disease severity, underscoring the need for more holistic clinical assessments.
An international study reveals...
06/17/2025
First Report Managed Care
News
Vitiligo Trial Assesses Ritlecitinib With nbUVB Under Modified Phototherapy Protocol
05/15/2025
Grace Taylor, MS, MA
An exploratory analysis of a phase 2b trial highlights the potential benefits and protocol adjustments of combining ritlecitinib with narrow-band narrow-band ultraviolet B (UVB) phototherapy for enhanced repigmentation in nonsegmental...
An exploratory analysis of a phase 2b trial highlights the potential benefits and protocol adjustments of combining ritlecitinib with narrow-band narrow-band ultraviolet B (UVB) phototherapy for enhanced repigmentation in nonsegmental...
An exploratory analysis of a...
05/15/2025
First Report Managed Care
News
Burden of Mild-to-Moderate Atopic Dermatitis: Real-World Insights From US Adults
05/09/2025
Juliet Gallagher
A recent study published by researchers utilizing data from the Adelphi Real World AD Disease Specific Programme™ provides a comprehensive assessment of the burden associated with mild-to-moderate atopic dermatitis (AD) in US adults.
A recent study published by researchers utilizing data from the Adelphi Real World AD Disease Specific Programme™ provides a comprehensive assessment of the burden associated with mild-to-moderate atopic dermatitis (AD) in US adults.
A recent study published by...
05/09/2025
First Report Managed Care
News
New Treatment for Vitiligo Offers Long-Term Cost Savings and High Repigmentation Success
04/14/2025
Lisa Kuhns, PhD, MD
A novel treatment for stable vitiligo combining autologous skin cell suspension (ASCS) with phototherapy has demonstrated both clinical success and long-term cost savings when compared to phototherapy alone, according to study results...
A novel treatment for stable vitiligo combining autologous skin cell suspension (ASCS) with phototherapy has demonstrated both clinical success and long-term cost savings when compared to phototherapy alone, according to study results...
A novel treatment for stable...
04/14/2025
First Report Managed Care
News
Patients With Vitiligo Face Elevated Risk of Cardiovascular Disease, Study Finds
03/14/2025
Grace Taylor, MS, MA
Individuals with vitiligo have an increased risk of major cardiovascular events, including stroke and venous thromboembolism, according to researchers.
Individuals with vitiligo have an increased risk of major cardiovascular events, including stroke and venous thromboembolism, according to researchers.
Individuals with vitiligo have...
03/14/2025
First Report Managed Care
News
Artificial Intelligence Enhances Facial Vitiligo Assessment With High Accuracy
02/18/2025
Lisa Kuhns, PhD, MD
A new artificial intelligence (AI) algorithm has demonstrated high accuracy in assessing facial vitiligo, offering a faster and more objective method for evaluating disease severity and treatment response, according to a study published in...
A new artificial intelligence (AI) algorithm has demonstrated high accuracy in assessing facial vitiligo, offering a faster and more objective method for evaluating disease severity and treatment response, according to a study published in...
A new artificial intelligence...
02/18/2025
First Report Managed Care
News
The Real-World Impact of Ruxolitinib Cream for Patients With Atopic Dermatitis
02/10/2025
Hannah Musick
The use of ruxolitinib cream for atopic dermatitis shows promise in decreasing the need for other treatments, with reductions in oral corticosteroid use observed in some patients.
The use of ruxolitinib cream for atopic dermatitis shows promise in decreasing the need for other treatments, with reductions in oral corticosteroid use observed in some patients.
The use of ruxolitinib cream for...
02/10/2025
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use